Kornimate/medical-research-clean huggingface dataset:
effects of parmigiano reggiano on muscle and inflammatory response to eccentric resistance training in older adults

Conditions: Atrophy, Muscular; Aging; Inflammation; Cholesterol Deposition

Summary: aging is associated with the loss of muscle mass and function (sarcopenia) and reduced tissue regenerative capacity. eccentric exercise (ecc) is a model of ret that can be used with the elderly, due to the ability of the muscle to combine high muscle strength production with low energy cost. ecc contractions are significantly more damaging to the muscles and produce greater muscle strength, for these reasons there is a greater risk of inducing muscle damage before the muscle is able to adapt. parmigiano reggiano (pr) has some peculiar bromatological characteristics. the proteins contained in it, and in particular the potentially bioactive peptide sequences, can rapidly provide the amino acids necessary to promote muscle growth and repair during exercise. furthermore, pr can be an important source of fatty acids, of which a significant amount of short-chain fatty acids (scfa) which are known to have important clinical effects on body composition and metabolic health and can have a systemic anti-inflammatory effect. therefore, the central hypothesize is that pr consumed while being engaged in a ret can provide more energy substrates and improve muscle recovery, redcue inflammatory markers and improve lipid metabolism. to date, no studies have studied its function on recovery from exercise nor in the elderly.


Eligibility criteria:
inclusion criteria: * age \>60 years * bmi \>18 and \<30 kg/m2 * stable body weight in the past 3 months * valid medical certifacate for practice of physical activity exclusion criteria: * diabetes or pre-diabetes as for ada guidelines * chronic diseases (cardiovascular, liver, respiratory, cancer, etc) * acute inflammatory status * regular practice of intense physical activity (\>2 sessions/week) * treatment with steroids in the past 3 months * regular use of \>50g/die of parmigiano reggiano
pilot study to assess the feasibility and initial efficacy of therapist-as-consultant, game-based ci therapy

Conditions: Stroke; Hemiparesis; Upper Extremity Dysfunction

Summary: pilot study to assess the feasibility and initial efficacy of therapist-as-consultant, game-based ci therapy. pre/post study design. participant received a target of 30 hours game-based motor intervention, 100 hours constraint of the less affected upper extremity, and 5 hours therapist consultation (including completion of a behavioral contract at the first study visit). duration of intervention was 10 consecutive weekdays, with pre-treatment and post-treatment testing performed within 1 week prior to and 1 week post-intervention by an independent tester.


Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures and be available for the duration of the study * male or female aged \> 17 * preserved ability to comprehend english and participate in basic elements of the therapy * community-dwelling * experienced mild to moderate hemiparesis at least six months prior * can independently operate the gaming system (those with severe cognitive impairments can usually achieve this) * corrected vision of at least 20/70 as assessed by their ability to identify game objects on the monitor from 5 feet away exclusion criteria: * concurrent participation in other experimental upper extremity trials * concurrent participation in other outpatient rehabilitation for their upper extremity * botox within the last 3 months (confound) * near-normal motor function (9-hole peg test score above the 10th percentile of a normative sample) * minimal nonuse (motor activity log at baseline \>2.5, accelerometry \> 60%) * major medical issues that would interfere with study treatments or make intensive rehabilitation difficult to tolerate
evaluation of the impact of a therapeutic education program for children with type 1 diabetes

Conditions: Diabetes Mellitus, Type I; Program Evaluation; Therapeutic Education; Children

Summary: the needs of children and teens with type 1 diabetes are very specific and different from the adults with type 1 diabetes. many organizations such as the world health organization or the international society for pediatric and adolescent diabetes, recommend a patient therapeutic education when it comes to children with type 1 diabetes. this study aims to evaluate the impact of a therapeutic education program on theoretical knowledge of the disease and also on quality of life, on biological and clinical indicators.

structuring a therapeutic education program for patients with a chronic disease was the initiative of the french high health authority in june 2007. the prevention and care of pediatric obesity and pediatric diabetes organization of mulhouse is a partner of the mulhouse hospital. besides the usual care given at the hospital of mulhouse for patients with a type 1 diabetes, both organizations also provide therapeutic education to these patients. each therapeutic education program is organized according to the patient's age. they can also be organized in a group or individually. the aim of the therapeutic education is to help the young patients to cope with diabetes in their daily activities. therapeutic education is known to bring good results for patients with diabetes, but there is no studies in france for children and teens with a type 1 diabetes.

Eligibility criteria:
inclusion criteria: * enrollment between january 15 to march 15, 2016 * insulin-dependent type 1 diabetes * treatment received at the hospital of mulhouse, france exclusion criteria: * opposition to study participation * behavioral issues * uncontrolled psychological issue

Keywords: evaluation therapeutic education type 1 diabetes children
the effect of real-time continuous glucose monitoring on severe complications to pregnancy in women with diabetes

Conditions: Diabetes; Pregnancy

Summary: the purpose of the study is to investigate the effects of real-time continuous glucose monitoring on severe complications to pregnancy in women with diabetes.

pregnancy outcome in women with type 1 or type 2 diabetes is still significantly poorer than in the background population. the prevalence of large fat babies (lga) is 50% in both types of diabetes, and perinatal death and preterm delivery is 4-7 times higher than in non-diabetic women. these complications are all closely related to non-optimal glycemic control in pregnancy, and improved metabolic control is crucial in our strive for improved pregnancy outcome in these patients. in 2007, a new generation of "real-time" continuous glucose monitoring (cgm) became available in denmark. these sensors estimate tissue glucose values automatically and frequently with immediate display of the glucose level. in addition it is possible to set alarms for high and low glucose levels, and the patient can react immediately with changes in diet or insulin dose. in this trial, 154 patients were randomized to either continuous glucose monitoring at five times in pregnancy in addition to standard care ot to unchanged standard care. the main aim is to evaluate if the use of cgm in pregnancy can reduce the prevalence of lga from 50 to 30%, but other outcome measurements such as preterm delivery, neonatal disease, hypoglycemia, low grade inflammation and vascular dysfunction, quality of life and self- care are also recorded.

Eligibility criteria:
inclusion criteria: * pregestational diabetes, type 1 or type 2 * single intrauterine pregnancy * at least 18 years old * informed consent exclusion criteria: * past gestational week 14 at inclusion * mental disorders * language barriere * gemelli * diabetic nephropathy

Keywords: real-time continuous glucose monitoring macrosomia
immunotherapy with cd19 car t-cells in patients with relapsed or refractory cd19+ leukemia and lymphoma

Conditions: Lymphoma Leukemia

Summary: b cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-hodgkin's lymphomas (nhl), lymphoblastic leukemias (all) and chronic lymphocytic leukemias (cll). current treatments for b cell malignancies include chemotherapy, radiation therapy, bone marrow transplantation, and peripheral blood stem cell transplantation. despite these treatment modalities, most patients will remain incurable. welgenaleucel (uwc19) is a cd19-directed genetically-modified autologous immunotherapy. this study is designed to evaluate safety and feasibility of administering welgenaleucel (uwc19) transduced with anti-cd19 lentiviral vector to patients with advanced refractory hematologic malignancies, including dlbcl and all.


Eligibility criteria:
inclusion criteria: * cd19+ leukemia or lymphoma patients with no available curative treatment options who have limited prognosis with currently available therapies * absolute lymphocyte count, alc )≧600/μl * hiv, htlv, syphilis negative * gpt ≦200 u/l * cr ≦221 umol/l * adequate venous access for apheresis, and no other contraindications for leukapheresis. * voluntary informed consent is given. exclusion criteria: * body weight \< 20kg * pregnant women. * uncontrolled active infection. * active hepatitis b or hepatitis c infection. * concurrent use of systemic steroids. recent or current use of inhaled steroids is not exclusionary. * previously treatment with any gene or cell therapy products. * any uncontrolled active medical disorder that would preclude participation as outlined. * expected survival\< 12 weeks * received investigational drug or device within 30 days pre-trial; * patients with any other serious diseases considered by the investigator(s) not in the condition to enter the trial.

Keywords: car-t cell, cd19, lymphoma, leukemia
prospective comparison of metolazone versus chlorothiazide for acute decompensated heart failure with diuretic resistance

Conditions: Heart Failure; Heart Failure With Reduced Ejection Fraction; Heart Failure Acute; Cardiovascular Diseases

Summary: the primary objective of the study is to compare efficacy of metolazone and chlorothiazide as add-on therapy in patients refractory to loop diuretics with heart failure with a reduced ejection fraction (hfref). this will be a single-center randomized pilot study.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * admitted for acute decompensated hf with left ventricular ejection fraction (lvef) \<40% * refractory fluid overload: * unresponsive (\<500 ml net negative over previous 24 hours) and ineffective diuresis (determined by hf team) to moderate intensity push or low intensity continuous infusion loop diuretic (80 mg iv furosemide or equivalent bumetanide dose of 4 mg) * english or spanish-speaking subjects * willing and able to comply with study procedures exclusion criteria: * baseline thiazide use prior to admission or prior to study enrollment * renal replacement therapies (rrt) or glomerular filtration rate (gfr) \<30 ml/min at the time of enrollment * pregnant women * cognitive impairment * prisoners * left ventricular assist devices (lvad) or temporary mechanical circulatory support devices * history of cardiac transplant * reported allergy to thiazides * no enteral access or unable to take medications enterally * palliative diuretics * systolic blood pressure (sbp) \<90 mm hg prior to randomization * patients receiving concomitant lithium therapy

Keywords: loop diuretics heart failure diuretic resistance thiazide diuretics
effect of a protein-enriched drink on muscle function

Conditions: Contracture

Summary: there is no conclusive evidence about the effect of intake of protein-enriched drink after and acute high intensity exercise bout on muscle function and damage. the investigators aimed to study the effect of a protein-enriched drink on muscle function recovery following an acute high intensity exercise bout. the present counterbalanced, crossover, and double blind study will involve a total of 12 active men.

participants will run downhill (-10%) during 30 min at a intensity equivalent to 75-80% of their maximum heart rate (previously determined). after the exercise bout, participants will have either the placebo or the experimental drink. the investigators will measure muscle function and damage-related parameters right after the exercise as well as the three following days. this protocol will be repeated after a wash out period of 3 weeks, where the participants will have the other drink. the investigators will control exercise and diet three weeks before study entry, during the experimental week as the investigators as during the wash out period.

Eligibility criteria:
inclusion criteria: * recreational triathletes with 2 years of experience * maximum oxygen uptake : ≥55 ml/kg/min * fat mass: 8-20% measured by dual energy x-ray absorptiometry * not participating in another study * not having ergogenic aids * not participating in a weight loss program * normal electrocardiogram * participants must be capable and willing to provide consent, understand exclusion criteria and accept the randomized group assignment exclusion criteria: * history of cardiovascular disease * diabetes or hypertension * medication for hypertension, hyperlipidemia, hyperuricemia or other illness. * smoking * other significant medical conditions that are life-threatening or that can interfere with or be aggravated by exercise. * unwillingness to either complete the study requirements or to be randomized into control or training group.

Keywords: muscle function anaerobic power muscle damage
nystatin pastilles for the prevention of oral candidiasis in patients with aids or arc

Conditions: Candidiasis, Oral; HIV Infections

Summary: to determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with aids or aids related complex (arc) (group iii or iv, cdc classification).


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * systemic or oral antibiotics. * experimental drugs (ind drugs) which are targeted specifically against the aids (group iv cdc classification) virus or stimulate the immune system. patients with the following conditions are included: * aids or aids related complex (arc) (hiv infection group 3 or 4, cdc classification) who have had culture-proven oral candidiasis clinically cured within 7 days of study entry and are likely to be compliant for the 20 weeks of nystatin pastille prophylaxis. * able to follow instructions regarding the use of a pastille. * patients entering part ii of this study (randomized double-blind) must have been clinically cured of oral candidiasis within 1 - 7 days of entry into this randomized study. * oral lesions such as kaposi's sarcoma, herpes zoster, and herpes simplex can be enrolled. exclusion criteria co-existing condition: patients with the following are excluded: * systemic candidiasis. * hypersensitivity to nystatin. * suspected or proven candidal esophagitis. patients with the following are excluded: * systemic candidiasis. * projected survival of less than 6 months. * unable to maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. * hypersensitivity to nystatin. * suspected or proven candidal esophagitis.

Keywords: nystatin aids-related opportunistic infections acquired immunodeficiency syndrome aids-related complex candidiasis, oral
resilient: a research study, looking at how ryzodeg® works in people with type 2 diabetes in local clinical practice in japan

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how ryzodeg® works in real world participants. participants will get ryzodeg® as prescribed to them by the study doctor. the study will last for about 6 to 8 months. the participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures related to recording of data according to the protocol * the decision to initiate treatment with commercially available insulin ryzodeg® has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study * male or female, age more than or equal to 20 years (the legal age of adulthood) at the time of signing informed consent * diagnosed with type 2 diabetes (t2d) for at least 26 weeks prior to signing informed consent * available and documented glycosylated haemoglobin (hba1c) value less than or equal to 12 weeks prior to initiation of ryzodeg® treatment * for at least 26 weeks prior to initiation of ryzodeg® treatment, one of the following must apply: a) treated with insulin glargine (iglar) (any formulation, including biosimilar iglar). b) treated with iglar (any formulation, including biosimilar iglar) and iglar u300 for at least 12 weeks prior to initiation of ryzodeg® exclusion criteria: * previous participation in this study. participation is defined as signed informed consent. * pregnancy * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * hypersensitivity to ryzodeg® or to any of the excipients * previously treated with ryzodeg®
a clinical research study testing ropinirole treatment for restless legs syndrome

Conditions: Restless Legs Syndrome (RLS); Restless Legs Syndrome

Summary: a 14-week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with restless legs syndrome (rls) in the united states.


Eligibility criteria:
inclusion criteria: * patients diagnosed with restless legs syndrome (rls) with symptoms such as: uncomfortable or "creepy-crawly" sensations in your legs, overwhelming urge to move your legs to relieve these sensations, sensations go away when you move your legs, or trouble falling asleep or staying asleep because of these symptoms. * patients must give written informed consent prior to any specific study procedures. exclusion criteria: * patients who suffer from narcolepsy, sleep terror disorder, sleepwalking disorder, or a breathing related sleep disorder. * patients diagnosed with renal failure (end-stage renal disease) iron deficient anemia or pregnancy. * patients suffering from other movement disorders (i.e. parkinson's disease). * patients who have medical conditions such as diabetes, peripheral neuropathy, rheumatoid arthritis, or fibromyalgia syndrome. * participation in any clinical drug or device trial in the last three months. other inclusion or exclusion criteria to be evaluated by the physician.

Keywords: fatigue sleep sleep disorder legs rls restless legs syndrome ropinirole
this study aims to explore the efficacy of hyperbaric oxygen in the treatment of flap ischaemic necrosis after breast cancer surgery

Conditions: Flap Necrosis; Flap Ischemia

Summary: the expectation of our study was to explore the efficacy of using hyperbaric oxygen to rescue flap ischaemic necrosis after breast cancer surgery.

hyperbaric oxygen is commonly used to improve tissue oxygen saturation rescue flap ischemia, and treatment of diabetic foot ulcers. in the current study, there are also a number of case reports attempting to explore the role of hyperbaric oxygen in the treatment of postoperative skin flaps and nipple areola necrosis after breast surgery and significant efficacy has been obtained. our study expects to use the treatment of hyperbaric oxygen to save patients with signs of flap ischemic necrosis after breast cancer surgery and to improve the quality of life and prognosis of patients.

Eligibility criteria:
inclusion criteria: 1. understand the study procedure, participate in the study voluntarily and sign the informed consent form 2. aged ≥ 18 years and ≤ 60 years, female 3. ecog 0-2 4. patients with the skin score degree of b-d and the skin area of 1-3 in the clavien-dindo classification after breast cancer surgery； exclusion criteria: 1. contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube dysfunction, recurrent episodes of vertigo), eye disease (retinal detachment). 2. pregnancy or lactation. 3. any other condition that the investigators think the patient is unsuitable for participation in the study
profiling neutrophil counts in patients on chemotherapy

Conditions: Neoplasms; Neutropenia; Febrile Neutropenia

Summary: the purpose of this trial is to observe the changes in white cell counts in patients with cancer during chemotherapy and to determine if changes in the white cell count in the early days during chemotherapy can be used as a predictor of severe neutropenia and its complications.

neutropenia is a low count of the type of white blood cells that fight bacterial infection. it is a common toxicity of chemotherapy given for cancer. when complicated by infection, it can necessitate urgent admission to hospital, and can be life-threatening. recovery of neutrophils is necessary prior to delivery of further chemotherapy. the information available on the changes of neutrophils during chemotherapy is limited by the frequency of blood tests which have historically required a venous blood sample and hence are burdensome to the patient. there are point-of-care medical devices which measure the white blood cell count from a capillary finger-prick sample, and can be used in the patient's home. the investigators aim to use such a device in this trial to; (i) observe the changes in white cell counts following chemotherapy delivery, (ii) determine if changes in the white cell count in the early days during chemotherapy can be used as a predictor of severe neutropenia and its complications. this trial forms part of a larger project in which the investigators are exploring the role of home blood count monitoring in the management of severe neutropenia and its complications, and exploring the potential for home blood count monitoring to be used to optimise the dose intensity and density of chemotherapy. this is a non-randomised trial in adults with solid tumours, recruiting from leeds teaching hospitals nhs trust only. consenting participants are required to have regular finger-prick blood tests up to a maximum frequency of daily for the duration of the first cycle of chemotherapy, most commonly 3 weeks. a nurse will visit the participant at home and use the hemocue® wbc diff to perform the test. this trial is funded by a technology strategy board (innovate uk) small business research initiative grant.

Eligibility criteria:
inclusion criteria: * solid tumour diagnosis. * adults ≥ 18 years. * receiving either single agent or combination cytotoxic chemotherapy alone or in combination with other targeted or immunotherapies. * participants can be receiving primary prophylactic antibiotics or gcsf. * live within boundaries of local care direct service provision. exclusion criteria: * inability to give informed consent. * concurrent haematological malignancy. * known bleeding disorder. * known sickle cell disease or β-thalassaemia major. * known poorly controlled anti-coagulation (inr \>3.5 within 6 months for those on warfarin).

Keywords: neoplasms neutropenia drug therapy hematologic tests point-of-care systems febrile neutropenia